[ CAS No. 4595-59-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 4595-59-9 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 4595-59-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 4595-59-9 ]

SDS Specification

Alternatived Products of [ 4595-59-9 ]

Product Details of [ 4595-59-9 ]

CAS No. :	4595-59-9	MDL No. :	MFCD00006117
Formula :	C₄H₃BrN₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	GYCPLYCTMDTEPU-UHFFFAOYSA-N
M.W :	158.98	Pubchem ID :	78344
Synonyms :

Calculated chemistry of [ 4595-59-9 ] Expand+

Physicochemical Properties

Num. heavy atoms :	7
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	2.0
Num. H-bond donors :	0.0
Molar Refractivity :	29.73
TPSA :	25.78 ?2

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.76 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.49
Log Po/w (XLOGP3) :	0.72
Log Po/w (WLOGP) :	1.24
Log Po/w (MLOGP) :	0.35
Log Po/w (SILICOS-IT) :	1.77
Consensus Log Po/w :	1.11

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.91
Solubility :	1.94 mg/ml ; 0.0122 mol/l
Class :	Very soluble
Log S (Ali) :	-0.84
Solubility :	23.0 mg/ml ; 0.145 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.49
Solubility :	0.512 mg/ml ; 0.00322 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.25

Safety of [ 4595-59-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 4595-59-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 4595-59-9 ]
Downstream synthetic route of [ 4595-59-9 ]

[ 4595-59-9 ] Synthesis Path-Upstream 1~2

1
[ 110-91-8 ]
[ 4595-59-9 ]
[ 57356-66-8 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2007, vol. 15, # 4, p. 1586 - 1605

2
[ 4595-59-9 ]
[ 23719-80-4 ]
[ 1346697-39-9 ]

Yield	Reaction Conditions	Operation in experiment
41%	With 2,3-dicyano-5,6-dichloro-p-benzoquinone In tetrahydrofuran at 20℃; for 17 h;	5-Bromopyrimidine (8 g, 50.3 mmol) was taken in anhydrous THF (160 mL) followed by the addition of cyclopropylmagnesium bromide (106 mL, 52.8 mmol, 0.5 M solution in THF) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour, and then treated with a solution of 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (1 1.42 g, 50.3 mmol) in THF (26 mL). The resultant brown mixture was allowed to stir at room temperature for 16 hours and then evaporated under reduced pressure. The brown solid was suspended in water and extracted with dichloromethane (3x50 mL). The combined organics were washed with a IN aqueous solution of sodium hydroxide (2x15 mL), water, and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude material was purified by silica gel chromatography using 160 g BIOTAGE.(R). column eluting with hexanes/EtOAc (9: 1) to provide Intermediate 61 as a pale yellow solid (4.1 g, 41 percent yield). MS (ES): m/z=199.05 [M+H]⁺. Intermediate 61 was used in the synthesis of Example 214.
20%	at 0 - 20℃; for 1 h; Inert atmosphere	To a solution of 5-bromopyrimidine (3 g, 18.87 mmol) in Et20 (120 mL) and THF (20ml) was added cyclopropylmagnesium bromide (39.6 mL, 19.81 mmol) at 0°C. The resulting white suspension was stirred at rt for lh and quenched with water (0.340 mL, 18.87 mmol) followed by addition of DDQ (4.28 g, 18.87 mmol) in THF (10ml). The resulting black mixture was stirred at room temperature overnight. The reaction mixture was extracted with EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with NaOH (IN) and brine. The crude product was purified by Biotage (0-15percent EtOAc/hexanes, 1.2L) to afford the title compound (700 mg, 20percent) as a yellow solid. ^XH NMR (500 MHz, CC1₃D) δ ppm 8.87 (1 H, s), 8.66 (1 H, s), 2.40-2.56 (1 H, m), 1.13-1.32 (4 H, m).
20%	Stage #1: at 0 - 20℃; Stage #2: With water; 2,3-dicyano-5,6-dichloro-p-benzoquinone In tetrahydrofuran; diethyl ether at 20℃;	Preparation 11 A: 5-Bromo-4-cyclopropylpyrimidine [00148] To a solution of 5-bromopyrimidine (3 g, 18.87 mmol) in Et₂0 (120 mL) and THF (20ml) was added cyclopropylmagnesium bromide (39.6 mL, 19.81 mmol) at 0 °C. The resulting white suspension was stirred at room temperature for lh and quenched with water (0.340 mL, 18.87 mmol) followed by addition of DDQ (4.28 g, 18.87 mmol) inTHF (10ml). The resulting black mixture was stirred at room temperature overnight. The reaction mixture was extracted with EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with NaOH (IN) and brine. The crude product was purified by BIOTAGE? (0-15percent EtOAc/hexanes, 1.2L) to afford the title compound (700 mg, 20percent) as a yellow solid. ^XH NMR (500 MHz, chloroform-d) δ ppm 8.87 (1 hr, s), 8.66 (1 hr, s), 2.40-2.56 (1 hr, m), 1.13-1.32 (4 hr, m).

Reference： [1] Patent: WO2012/15723, 2012, A1, . Location in patent: Page/Page column 107; 108
[2] Patent: WO2012/9510, 2012, A1, . Location in patent: Page/Page column 54; 55
[3] Patent: WO2013/49263, 2013, A1, . Location in patent: Paragraph 00147; 00148

[ 4595-59-9 ] Synthesis Path-Downstream 1~13

1
[ 4595-59-9 ]
[ 704-38-1 ]
[ 108395-04-6 ]

Reference： [1]Journal of Medicinal Chemistry,1987,vol. 30,p. 1359 - 1365

2
[ 4595-59-9 ]
[ 342-25-6 ]
α-(2-fluorophenyl)-α-(4-fluorophenyl)-5-pyrimidinemethanol [ No CAS ]

Reference： [1]Bioscience, Biotechnology and Biochemistry,2001,vol. 65,p. 817 - 822

3
[ 4595-59-9 ]
[ 57260-71-6 ]
[ 634468-96-5 ]

Yield	Reaction Conditions	Operation in experiment
58.7%	With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 90℃; for 12h;	(1) Preparation of tert-butyl 4-(pyrimidin-5-yl)piperazin-1-carboxylate To a 100 mL eggplant-shaped bottle were added 5-bromopyrimidine (3.16 g, 20 mmol), tert-butyl piperazin-1-carboxylate (3.72 g, 20 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (2.49 g, 4 mmol), cesium carbonate (13.0 g, 40 mmol) and tris(dibenzylideneacetone)dipalladium (1.83 g, 2 mmol); and toluene (80 mL) was added. The reaction was carried out at 90Cunder the protection of nitrogen for 12 h. The mixture was filtrated under suction, the filtrate was concentrated, and the crude product was purified by silica gel column chromatography (dichloromethane: methanol=50:1) to get the title compound (3.1 g, yield: 58.7%).
		Argon is bubbled for 15 minutes into a mixture of 9.3 g of tert-butyl 1-piperazinecarboxylate, 7.95 g of 5-bromopyrimidine and 6.5 g of sodium tert-butoxide in 250 ml of toluene, which is then heated at reflux, 0.277 g of palladium acetate and 1.7 ml of tri-tert-butylphosphine are added and reflux is continued for 24 hours. 0.277 g of palladium acetate is added and the mixture is heated at reflux for 8 hours. The reaction mixture is cooled to AT, water is added, the mixture is subjected to extraction with AcOEt, the organic phase is filtered and dried over Na2SO4 and the solvent is evaporated under vacuum. The residue is chromatographed on silica gel, eluting with DCM, then with a DCM/AcOEt (50/50; v/v) mixture and finally with a DCM/MeOH (95/5; v/v) mixture. This gives 3.95 g of the expected product following recrystallization from a DCM/hexane/iso ether mixture.
	With tris-(dibenzylideneacetone)dipalladium(0); potassium tert-butylate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; In toluene; for 16h;Reflux; Inert atmosphere;	General procedure: 2-Chloro-4-iodotoluene (250muL, 1.78mmol), 1-Boc-piperazine (398mg, 2.14mmol), Pd2(dba)3 (40.8mg, 0.045mmol), Xantphos (103mg, 0.178mmol) and potassium tert-butoxide (280mg, 2.50mmol) were dissolved in toluene (5mL) and heated at reflux for 16h under N2. The reaction was then concentrated and dissolved in EtOAc (20mL), filtered through celite and washed with additional EtOAc (50mL). The organic layer was washed with water (2×20mL) and brine (2×20mL), then dried with Na2SO4 and concentrated in vacuo. The crude residue was then purified by column chromatography (100% CyHex to 10% EtOAc/CyHex) to obtain the protected intermediate as an oil (436mg, 79%). MS, m/z=311 (100) [M+H]+, 313 (30). The intermediate was then dissolved in a 1:3 mixture of TFA/DCM (4mL) and stirred at 20C for 1h. The solvent was then evaporated in vacuo and the crude residue dissolved in EtOAc (10mL) which was then successively washed with a 10% NaHCO3 solution (10mL), water (10mL) and brine (10mL). The organic layer was then dried with Na2SO4 and concentrated in vacuo to obtain 106 as a solid (288mg, 97%).

Reference： [1]Tetrahedron Letters,2006,vol. 47,p. 2549 - 2552
[2]Patent: EP3091008,2016,A1 .Location in patent: Paragraph 0380; 0381
[3]Patent: US2005/176722,2005,A1 .Location in patent: Page/Page column 20
[4]European Journal of Medicinal Chemistry,2020,vol. 195

4
[ 4595-59-9 ]
[ 612832-83-4 ]
5-[2-(benzyloxy)-3-chlorophenyl]pyrimidine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,4-dioxane; for 48h;Heating / reflux;	A mixture of the product from step (ii) (0.2g), 5-BROMOPYRIMIDINE (0.16g), sodium carbonate (0.21g) and tetrakistriphenylphosphine palladium (0) (0. 05g) in dioxane (6ML) was heated under reflux for 48h. The mixture was partitioned between EtOAc and water, the organics separated, dried, and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 20% EtOAc/isohexane. Yield 0.283g. MS: APCI (+ve): 297/9 (M+1)

Reference： [1]Patent: WO2004/89885,2004,A1 .Location in patent: Page 34

5
[ 1455-20-5 ]
[ 4595-59-9 ]
[ 1186368-92-2 ]

Reference： [1]Green Chemistry,2009,vol. 11,p. 425 - 432

6
[ 4595-59-9 ]
[ 21230-43-3 ]
[ 1335299-94-9 ]

Yield	Reaction Conditions	Operation in experiment
69%	With potassium carbonate;palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; In o-xylene; water; at 140℃; for 17h;Inert atmosphere;	Step 1: 1-Methyl-3-(pyrimidin-5-ylamino)-1H-pyrazole-4-carboxylic acid ethyl ester Under an atmosphere of argon, palladium(II) acetate (79 mg), and subsequently xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 256 mg) was added to a mixture of 5-bromopyridine (2.0 g), <strong>[21230-43-3]3-amino-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester</strong> (1.5 g), K2CO3 (2.2 g), water (0.33 ml), and o-xylene (20 ml). The mixture was heated to 140 C. for 17 h. Upon cooling and addition of dichloromethane (50 ml), the mixture was filtered and concentrated under vacuum. The title compound (1.52 g, 69%) was obtained from the residue by column chromatography (silica gel, cyclohexane/ethyl acetate gradient). MS (m/e)=248.2 [M+H+].
69%	With potassium carbonate;palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; In o-xylene; water; at 140℃; for 17h;	Under an atmosphere of argon, palladium(II) acetate (79 mg), and subsequently xantphos (4,5- bis(diphenylphosphino)-9,9-dimethylxanthene, 256 mg) was added to a mixture of 5- bromopyridine (2.0 g), 3-amino-l-methyl-lH-pyrazole-4-carboxylic acid ethyl ester (1.5 g), 2CO3 (2.2 g), water (0.33 ml), and o-xylene (20 ml). The mixture was heated to 140C for 17 h. Upon cooling and addition of dichloromethane (50 ml), the mixture was filtered andconcentrated under vacuum. The title compound (1.52 g, 69%) was obtained from the residue by column chromatography (silica gel, cyclohexane / ethyl acetate gradient).MS (m/e) = 248.2 [M+H+].

Reference： [1]Patent: US2011/237564,2011,A1 .Location in patent: Page/Page column 36
[2]Patent: WO2011/117264,2011,A1 .Location in patent: Page/Page column 94

7
[ 4595-59-9 ]
[ 59418-09-6 ]
[ 1362690-96-7 ]
[ 1372926-66-3 ]

Reference： [1]Chemistry - A European Journal,2011,vol. 17,p. 14450 - 14463

8
[ 4595-59-9 ]
[ 850567-56-5 ]
[ 1400287-54-8 ]

Yield	Reaction Conditions	Operation in experiment
84%	With sodium carbonate;dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; In 1,2-dimethoxyethane; water; at 150℃; for 0.25h;Microwave irradiation;	Preparation 134: 2-Chloro-4-(pyrimidin-5-yl)aniline; [00304] To a mixture of 4-amino-3-chlorophenylboronic acid pinacol ester (0.1 10g, 0.434 mmol), 5-bromopyrimidine (0.090 g, 0.56 mmol), 1 ,1 '- bis(diphenylphosphino)ferrocene)-dichloropalladium(ll) DCM complex (23 mg, 0.028 mmol) was added anhydrous DME (3.0 mL) followed by 2M aqueous sodium carbonate (0.53 mL, 1 .06 mmol). The microwave vial was heated at 150C for 15 minutes under microwave irradiation. The reaction was partitioned between ethyl acetate (60 mL) and a saturated aqueous NaHC03 solution (15 mL). The organic layer was washed with a saturated aqueous NaHC03 solution (15 mL), dried (Na2S04) and concentrated in vacuo. The residue was purified using preparative TLC eluting with 20% ethyl acetate in CH2CI2. The product band was recovered and stirred with 2% MeOH in ethyl acetate / CH2CI2 (v/v; 1 :5) (20 mL). The silica was removed by filtration, washed with ethyl acetate / CH2CI2 (v/v; 1 :1 ) (2 x 5 mL) and acetone (3 x 4 mL) to give the title compound as a white solid (0.075 g, 84%). 1 H-NMR (500 MHz, DMSO-d6) 5.72 (s, 2H), 6.91 (d, J = 8.4, 1 H), 7.51 (dd, J = 2.2, 8.3 Hz, 1 H), 7.72 (d, J = 2.2 Hz, 1 H), 9.04, 9.05 (2 x s, 3H).

Reference： [1]Patent: WO2012/123745,2012,A1 .Location in patent: Page/Page column 106-107

9
[ 4595-59-9 ]
[ 957121-05-0 ]
[ 1428881-81-5 ]

Yield	Reaction Conditions	Operation in experiment
24%	With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,2-dimethoxyethane; ethanol; water; at 70.0℃; for 12.0h;Sealed tube; Inert atmosphere;	Preparation 75A: 2-Fluoro-3-( rimidin-5-yl)benzonitrile[00274] A sealed tube apparatus was charged with a solution containing 5- bromopyrimidine (1 g, 6.29 mmol), sodium carbonate (3.33 g, 31.4 mmol), and 3-cyano- 2-fluorophenylboronic acid (1.037 g, 6.29 mmol) in a mixture of DME (Ratio: 2, Volume: 31.4 ml), water (Ratio: 1.000, Volume: 15.72 ml), and EtOH (Ratio: 1.000, Volume: 15.72 ml) at ambient temperature. Tetrakis(triphenylphosphine) palladium(O) (0.363 g, 0.314 mmol) was then added and the system was purged with nitrogen, sealed, and heated to 70 C for 12h. The vessel was cooled to room temperature and diluted with EtOAc and water. The mixture was further diluted with brine and extracted three times with EtOAc. The combined organics were dried over MgS04, filtered, and concentrated to give the crude product. The crude material was purified by flash chromatography on silica using an ISCO machine (40 g S1O2 column, 40 mL/min, 0-40% EtOAc/hexanes over 15 minutes, tr = 8 minutes) to afford the title compound (300 mg, 24%). ESI MS (M+H)+ = 200.0. ? NMR (400 MHz, DMSO-d6) delta ppm 9.28 (1 hr, s), 9.09 (2 hr, d, J=1.54 Hz), 8.02-8.12 (2 hr, m), 7.59 (1 hr, t, J=7.81 Hz).

Reference： [1]Patent: WO2013/49263,2013,A1 .Location in patent: Paragraph 00273; 00274

10
[ 4595-59-9 ]
[ 721960-43-6 ]
[ 1400287-54-8 ]

Yield	Reaction Conditions	Operation in experiment
84%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate; In 1,2-dimethoxyethane; water; at 150℃; for 0.25h;Microwave irradiation;	Preparation 134 2-Chloro-4-(pyrimidin-5-yl)aniline To a mixture of <strong>[721960-43-6]4-amino-3-chlorophenylboronic acid pinacol ester</strong> (0.110 g, 0.434 mmol), 5-bromopyrimidine (0.090 g, 0.56 mmol), 1,1'-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) DCM complex (23 mg, 0.028 mmol) was added anhydrous DME (3.0 mL) followed by 2M aqueous sodium carbonate (0.53 mL, 1.06 mmol). The microwave vial was heated at 150 C. for 15 minutes under microwave irradiation. The reaction was partitioned between ethyl acetate (60 mL) and a saturated aqueous NaHCO3 solution (15 mL). The organic layer was washed with a saturated aqueous NaHCO3 solution (15 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified using preparative TLC eluting with 20% ethyl acetate in CH2Cl2. The product band was recovered and stirred with 2% MeOH in ethyl acetate/CH2Cl2 (v/v; 1:5) (20 mL). The silica was removed by filtration, washed with ethyl acetate/CH2Cl2 (v/v; 1:1) (25 mL) and acetone (34 mL) to give the title compound as a white solid (0.075 g, 84%). 1H-NMR (500 MHz, DMSO-d6) 5.72 (s, 2H), 6.91 (d, J=8.4, 1H), 7.51 (dd, J=2.2, 8.3 Hz, 1H), 7.72 (d, J=2.2 Hz, 1H), 9.04, 9.05 (2*s, 3H).

Reference： [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 10045 - 10065
[2]Patent: US2013/345181,2013,A1 .Location in patent: Paragraph 0749

11
[ 4595-59-9 ]
[ 214360-60-8 ]
[ 1596358-25-6 ]

Yield	Reaction Conditions	Operation in experiment
80%		A similar procedure22 to that previously described for the preparation of 98 was followed using 4-acetamidophenylboronic acid pinacol ester (91) (0.10 g, 0.38 mmol), 5bromopyrimidine (93) (73 mg, 0.46 mmol), sodium hydrogen carbonate (97 mg, 1.15 mmol) and bis(triphenylphosphine)palladium(II) chloride (14 mg, 0.02 mmol) in toluene (2 mL), ethanol (1 mL) and water (0.5 mL). Purification by flash chromatography (hexane:ethyl acetate 1:1) afforded 99 as a pale brown solid (65 mg, 0.30 mmol, 80%). Rf = 0.15 (hexane:ethyl acetate, 1:1); mp 185-190 C; 1H NMR (400MHz; CDCl3) deltaH 2.19 (3H, s, CH3), 3.71 (1H, s, NH), 7.55 (2H, d, J = 8.6 Hz, H-2', H-6'), 7.74 (2H, d, J = 8.6 Hz, H-3', H-5'), 8.94 (2H, s, H-4, H-6) and 9.13 (1H, s, H-2); 13C NMR (100MHz, CDCl3) deltaC 23.7 (CH3), 120.4 (CH), 127.2 (CH), 128.8 (C), 134.0 (C), 139.5 (C), 154.3 (CH), 156.4 (CH) and 169.8 (C); IR (numax/cm-1) 826, 841, 1194, 1325 (C-N), 1416, 1517, 1541, 1600 (N-H), 1667 (C=O), 2852, 2923, 3043, 3097 and 3238 (N-H); MS (ESI, 70 eV) m/z 236 (MNa+, 100%); Found (MNa+, 236.0794), C12H11N3NaO requires 236.0794.

Reference： [1]Bioorganic and Medicinal Chemistry,2014,vol. 22,p. 2220 - 2235

12
[ 4595-59-9 ]
[ 348-59-4 ]
[ 1638159-46-2 ]

Reference： [1]Advanced Synthesis and Catalysis,2014,vol. 356,p. 1586 - 1596

13
[ 4595-59-9 ]
[ 151169-74-3 ]
5-(2,3-dichlorophenyl)pyrimidine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93%	With potassium phosphate; tetrakis(triphenylphosphine) palladium(0); In 1,4-dioxane; water;	The compound 3a was synthesized in a solvent system of dioxane:water (5 mL: 1 mL), by treating 0.100 g of 5-bromopyrimidine(0.629 mmol) with 0.149 g of 4-biphenylboronic acid (0.754 mmol)along with 0.160 g of K 3 PO 4 (0.754 mmol) base and 0.014 g ofPd(PPh 3 ) 4 (2.00 mol%) catalyst Yellowish white solid compoundC 16 H 12 N 2 (i.e. 3a) was obtained with mp 65-70 C and Yield 87%.1 HNMR (CDCl 3 , 400 MHz) δ = 9.23 (s, 1H), 9.03 (s, 2H), 7.77 (d, 2H,J = 12.00 Hz), 7.65 (m, 4H), 7.49 (t, 2H, J = 8.00 Hz), 7.40 (m, 1H)(Fig. S1), 13 C NMR (CDCl 3 , 100 MHz) δ = 155.67 (CH), 154.61 (CH),142.57 (C), 139.84 (C), 134.54 (C), 132.06 (C), 129.02 (CH),128.35(CH), 128.04 (CH),127.45 (CH),127.14 (CH) (Fig. S2), IR (neat, cm -1 )υ = 3033 (s), 1541 (s), 1488 (m), 1408 (s), 998 (m), 844 (m), 766(s), 724 (m), 688 (m), 629 (w-m), 569 (w), 515 (w) (Fig. S3), ElementalAnalysis: C, 82.73; H, 5.21; N, 12.06.

Reference： [1]Journal of Molecular Structure,2021,vol. 1237

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

? Alkyl Halide Occurrence ? General Reactivity ? Grignard Reaction ? Hiyama Cross-Coupling Reaction ? Kinetics of Alkyl Halides ? Kumada Cross-Coupling Reaction ? Reactions of Alkyl Halides with Reducing Metals ? Reactions of Amines ? Reactions of Dihalides ? Stille Coupling ? Substitution and Elimination Reactions of Alkyl Halides ? Suzuki Coupling

Historical Records

Related Functional Groups of
[ 4595-59-9 ]

Bromides

[ 7752-82-1 ]

5-Bromopyrimidin-2-amine

Similarity: 0.85

[ 7752-78-5 ]

5-Bromo-2-methylpyrimidine

Similarity: 0.83

[ 1439-09-4 ]

5-Bromo-4-methylpyrimidine

Similarity: 0.81

[ 32779-37-6 ]

2,5-Dibromopyrimidine

Similarity: 0.81

[ 1193116-74-3 ]

5-Bromo-2-(bromomethyl)pyrimidine

Similarity: 0.77

Related Parent Nucleus of
[ 4595-59-9 ]

Pyrimidines

[ 7752-82-1 ]

5-Bromopyrimidin-2-amine

Similarity: 0.85

[ 7752-78-5 ]

5-Bromo-2-methylpyrimidine

Similarity: 0.83

[ 1439-09-4 ]

5-Bromo-4-methylpyrimidine

Similarity: 0.81

[ 32779-37-6 ]

2,5-Dibromopyrimidine

Similarity: 0.81

[ 1193116-74-3 ]

5-Bromo-2-(bromomethyl)pyrimidine

Similarity: 0.77

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

[ CAS No. 4595-59-9 ] {[proInfo.proName]}

Quality Control of [ 4595-59-9 ]

Related Doc. of [ 4595-59-9 ]

Product Details of [ 4595-59-9 ]

Calculated chemistry of [ 4595-59-9 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 4595-59-9 ]

Application In Synthesis of [ 4595-59-9 ]

[ 4595-59-9 ] Synthesis Path-Upstream 1~2

[ 4595-59-9 ] Synthesis Path-Downstream 1~13

Technical Information

Related Functional Groups of [ 4595-59-9 ]

Bromides

Related Parent Nucleus of [ 4595-59-9 ]

Pyrimidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 4595-59-9 ]

Related Parent Nucleus of
[ 4595-59-9 ]